GNCAQ

0.00010.00%
KS

Katrine S. Bosley

Independent Director

Ms. Katrine S. Bosley serves as a Venture Partner at Advent Life Sciences LLP since joining in May 26, 2022. She served as Chairman of the Board at Arrakis Therapeutics, Inc until June 2026. She is a founding CEO of DaCapo Brainscience. She serves as Director at Massachusetts Eye and Ear Infirmary, Inc. She served as Member of Supervisory Board at Galapagos NV since April 28, 2020 until April 2022. She served as Independent Non-Executive Director at Galapagos NV since March 4, 2013 until April 28, 2020. Ms. Bosley served as President of Editas Medicine Inc. from June 24, 2014 to March 01, 2019. Ms. Bosley had been the Chief Executive Officer of Editas Medicine Inc. from June 24, 2014 to March 01, 2019. Ms. Bosley served as the Chief Executive Officer at Celgene Avilomics Research, Inc. She served as Vice President of Business Development at Adnexus Therapeutics Inc. She served as Vice President of Strategic Operations at Adnexus Therapeutics Inc. since August 2004. She has been a leader in emerging companies with broad platforms for innovative medicines. She has expertise in the biotechnology industry in the U.S. and in Europe. Prior to joining Compound Therapeutics Inc. in September 20, 2004, she spent years with Biogen Idec, Inc. in a variety of corporate and business development roles and served as its Director of Decision Support from 1995 to 2004. She managed commercial analysis for Avonex and Amevive, including market research, sales forecasting and other analytical functions. At Biogen Idec, she had roles in business development, commercial operations and portfolio strategy in the U.S. and Europe. From 1993 to 1995, Ms. Bosley served as Analyst for Highland Capital Partners, a venture capital firm. During her tenure at Biogen Idec, she completed a number of business transactions and she led the deal between Biogen and Elan Pharmaceuticals for Antegren (natalizumab). She served as Chief Executive Officer of Avila from May 2009 to March 2012. She contributed to collaborations with Merck, Inhale Therapeutic Systems (Nektar), NsGene, Ontogeny (Curis) and others spending part of her time based out of Biogen’s European Headquarters in Paris. She led the corporate long-range plan and portfolio prioritization processes, conducted market research and developed product positioning for early stage products and served as Manager of Investor Relations. Ms. Bosley was part of the healthcare team at Highland Capital Partners, where she evaluated investment opportunities in biotechnology, medical device and healthcare service companies. She had been Chair of the Board at Genocea Biosciences, inc. from August 2013 to December 2018. She was also in regulatory affairs at Alkermes, Inc. and coordinated the filing of their first IND. She had been Director at Editas Medicine Inc. from June 2014 to March 01, 2019. Ms. Bosley served as President, Celgene Avilomics Research at Celgene from March 2012 to May 2012. She serves as a Director of Coco Therapeutics. She has been an Independent Director of Genocea Biosciences, Inc., since March 2013. She serves as a Director of Avila Therapeutics, Inc. She served as a Director of Scholar Rock, Inc. until May 25, 2017. She served as a Director of Scholar Rock Holding Corp. until February 21, 2017. Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute, Inc. from September 2013 to May 2014. Ms. Bosley graduated with a B.A. in biological sciences from Cornell University and completed the Program for Management Development at Harvard Business School. Katrine has been recognized as one of the 100 Most Creative People in Business by Fast Company, as CEO of the Year by Xconomy, as one of 30 Global Game Changers by Forbes, as Entrepreneur of the Year by the New England Venture Capital Association and as one of the Top Ten Women in Biotech by Fierce Biotech.

Positions